Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A new look at levodopa based on the ELLDOPA study.

S Fahn1

  • 1Department of Neurology, Columbia University, New York, NY, USA. fahn@neuro.columbia.edu

Journal of Neural Transmission. Supplementum
|October 5, 2006
PubMed
Summary

The ELLDOPA study investigated levodopa

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alpha galactosidase A activity in Parkinson's disease.

Neurobiology of disease·2018
Same author

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy.

Movement disorders : official journal of the Movement Disorder Society·2017
Same author

Inpatient treatment for functional neurologic disorders.

Handbook of clinical neurology·2016
Same author

Increased Rate of Sporadic and Recurrent Rare Genic Copy Number Variants in Parkinson's Disease Among Ashkenazi Jews.

Molecular genetics & genomic medicine·2013
Same author

Network correlates of disease severity in multiple system atrophy.

Neurology·2012
Same author

Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study.

Neurology·2012

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Levodopa is the primary Parkinson's disease (PD) treatment, but concerns exist regarding motor complications and potential neurotoxicity.
  • Delayed levodopa initiation was common due to fears of exacerbating neurodegeneration and motor issues.
  • Dopamine agonists offered an alternative but with lower efficacy and their own side effects.

Observation:

  • The ELLDOPA study aimed to test if levodopa enhances PD progression via oxidative stress.
  • Clinical results after levodopa withdrawal showed less symptom progression compared to placebo.
  • A dose-response relationship suggested potential neuroprotective effects of levodopa.

Findings:

  • The clinical arm of ELLDOPA did not support the hypothesis of levodopa-induced neurotoxicity.
  • Evidence suggested levodopa might slow PD symptom progression.
  • Conflicting neuroimaging results and short withdrawal periods created uncertainty about neuroprotection.

Implications:

  • The ELLDOPA study failed to alter current clinical practice regarding levodopa initiation.
  • Most neurologists remain unconvinced of levodopa's neuroprotective or neurotoxic effects.
  • Further robust evidence is required to change established treatment paradigms for Parkinson's disease.

Related Experiment Videos